tiprankstipranks
Trending News
More News >
Pharming Group (PHGUF)
OTHER OTC:PHGUF
US Market
Advertisement

Pharming Group (PHGUF) Earnings Dates, Call Summary & Reports

Compare
96 Followers

Earnings Data

Report Date
Mar 12, 2026
Before Open (Confirmed)
Period Ending
2025 (Q4)
Consensus EPS Forecast
<0.01
Last Year’s EPS
<0.01
Same Quarter Last Year
Moderate Buy
Based on 0 Analysts Ratings

Earnings Call Summary

Q3 2025
Earnings Call Date:Nov 06, 2025|
% Change Since:
|
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance with significant revenue growth and upgraded guidance. RUCONEST and Joenja both showed robust performance, and the company's cash position has been restored. However, there is a planned withdrawal of RUCONEST from certain markets due to financial sustainability concerns. Overall, the positive aspects significantly outweigh the lowlight.
Company Guidance
During the third quarter of 2025, Pharming Group N.V. reported a robust performance, with total revenues increasing by 30% compared to the same period in the previous year. Operating profit soared to $15.8 million, nearly four times the result of Q3 2024, supported by an operating cash flow of $32 million. The company's strong financial results were largely driven by significant growth in its two primary commercial products: RUCONEST and Joenja, which saw revenue increases of 29% and 35% year-on-year, respectively. This performance led to an upgrade in Pharming's full-year 2025 revenue guidance, now projected between $365 million and $375 million, up from the previous range of $335 million to $350 million. The company also highlighted a gross margin improvement to 93% and noted a strategic reduction in G&A headcount to optimize capital deployment. Pharming continues to leverage its strong rare disease capabilities to build a leading global rare disease company, with a promising late-stage pipeline poised to deliver further growth.
Strong Revenue Growth
Total revenues grew by 30% in Q3 2025 versus the same quarter last year, and operating profit jumped to $15.8 million, nearly 4x last year's result.
RUCONEST and Joenja Performance
RUCONEST revenue grew 29% year-on-year, driven by new prescribers and patient enrollments. Joenja third quarter revenue increased by 35%, reflecting strong patient growth and new patient identification.
Upgraded Revenue Guidance
The company raised its full-year 2025 revenue guidance to $365 million to $375 million from the previous $335 million to $350 million.
Cash Position Recovery
Operating cash flow was $32 million, bringing the cash position nearly back to its level before the Abliva acquisition at the end of 2024.
Pipeline Advancements
Progress in the pipeline includes Phase II proof-of-concept studies for PIDs with immune dysregulation, and a registrational study for KL1333 in primary mitochondrial disease.

Pharming Group (PHGUF) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

PHGUF Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Mar 12, 2026
2025 (Q4)
<0.01 / -
0.005
Nov 06, 2025
2025 (Q3)
0.00 / 0.01
-0.002600.00% (+0.01)
Jul 31, 2025
2025 (Q2)
-0.01 / <0.01
-0.002400.00% (<+0.01)
May 08, 2025
2025 (Q1)
>-0.01 / -0.02
-0.019-15.79% (>-0.01)
Mar 13, 2025
2024 (Q4)
<0.01 / <0.01
-0.004225.00% (<+0.01)
Oct 24, 2024
2024 (Q3)
0.00 / >-0.01
0
Aug 01, 2024
2024 (Q2)
0.00 / >-0.01
0.001-300.00% (>-0.01)
May 08, 2024
2024 (Q1)
<0.01 / -0.02
-0.017-11.76% (>-0.01)
Mar 14, 2024
2023 (Q4)
0.00 / >-0.01
-0.0280.00% (+0.02)
Oct 26, 2023
2023 (Q3)
-0.01 / 0.00
0.04
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

PHGUF Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 06, 2025
$1.20$1.53+27.50%
Jul 31, 2025
$0.98$0.980.00%
May 08, 2025
$0.88$0.880.00%
Mar 13, 2025
$0.79$0.90+13.92%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Pharming Group (PHGUF) report earnings?
Pharming Group (PHGUF) is schdueled to report earning on Mar 12, 2026, Before Open (Confirmed).
    What is Pharming Group (PHGUF) earnings time?
    Pharming Group (PHGUF) earnings time is at Mar 12, 2026, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is PHGUF EPS forecast?
          PHGUF EPS forecast for the fiscal quarter 2025 (Q4) is <0.01.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis